ATE448775T1 - Rifalazil zur behandlung von infektionen mit clostridium difficile - Google Patents

Rifalazil zur behandlung von infektionen mit clostridium difficile

Info

Publication number
ATE448775T1
ATE448775T1 AT03749288T AT03749288T ATE448775T1 AT E448775 T1 ATE448775 T1 AT E448775T1 AT 03749288 T AT03749288 T AT 03749288T AT 03749288 T AT03749288 T AT 03749288T AT E448775 T1 ATE448775 T1 AT E448775T1
Authority
AT
Austria
Prior art keywords
rifalazil
clostridium difficile
treatment
difficile infections
infections
Prior art date
Application number
AT03749288T
Other languages
English (en)
Inventor
Barry Eisenstein
Original Assignee
Activbiotics Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Activbiotics Pharma Llc filed Critical Activbiotics Pharma Llc
Application granted granted Critical
Publication of ATE448775T1 publication Critical patent/ATE448775T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03749288T 2002-08-29 2003-08-29 Rifalazil zur behandlung von infektionen mit clostridium difficile ATE448775T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40687302P 2002-08-29 2002-08-29
US44457003P 2003-02-03 2003-02-03
PCT/US2003/027305 WO2004019907A1 (en) 2002-08-29 2003-08-29 Methods and reagents for treating infections of clostridium difficile and diseases associated therewith

Publications (1)

Publication Number Publication Date
ATE448775T1 true ATE448775T1 (de) 2009-12-15

Family

ID=31981443

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03749288T ATE448775T1 (de) 2002-08-29 2003-08-29 Rifalazil zur behandlung von infektionen mit clostridium difficile

Country Status (10)

Country Link
US (1) US20040106590A1 (de)
EP (1) EP1545453B1 (de)
JP (1) JP2006501310A (de)
AT (1) ATE448775T1 (de)
AU (2) AU2003268330A1 (de)
CA (1) CA2495144A1 (de)
DE (1) DE60330161D1 (de)
ES (1) ES2339003T3 (de)
TW (1) TW200500071A (de)
WO (1) WO2004019907A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
US20090149453A1 (en) * 2002-05-23 2009-06-11 Activbiotics Pharma Llc Methods and compositions for treating bacterial infections and diseases associated therewith
US20040077533A1 (en) * 2002-05-23 2004-04-22 Sayada Chalom B. Methods and compositions for treating bacterial infections and diseases associated therewith
TW200418485A (en) * 2002-09-23 2004-10-01 Activbiotics Inc Rifalazil compositions and therapeutic regimens
EP1663107A4 (de) * 2003-08-22 2010-06-23 Activbiotics Pharma Llc Rifamycin-analoga und ihre verwendungen
US7820652B2 (en) * 2003-09-24 2010-10-26 Activbiotics Pharma, Llc Regimen for the administration of rifamycin-class antibiotics
CA2549001A1 (en) * 2003-12-10 2005-06-30 Activbiotics, Inc. Rifamycin analogs and uses thereof
WO2005062882A2 (en) * 2003-12-23 2005-07-14 Activbiotics, Inc Rifamycin analogs and uses thereof
CA2470090A1 (fr) * 2004-06-18 2005-12-18 Bio-K Plus International Inc. Bacteries lactiques et leurs usages dans la prevention de diarrhee associee aux antibiotiques
FR2882522B1 (fr) * 2005-02-25 2007-04-13 Aventis Pharma Sa Composition pharmaceutique solide comprenant de la telithromycine
CN100398546C (zh) * 2005-06-29 2008-07-02 上海医药科技发展有限公司 碳青霉烯类抗生素法罗培南钠的制备方法
CN101340895A (zh) * 2005-12-22 2009-01-07 惠氏公司 包含替加环素的口服制剂
BRPI0620430A2 (pt) * 2005-12-22 2011-11-08 Wyeth Corp métodos para tratar infecções do trato gastrointestinal com tigeciclina
MX2008012844A (es) * 2006-04-06 2009-01-19 Activbiotics Pharma Llc Composiciones farmaceuticas y usos de ellas.
EA017564B1 (ru) * 2007-09-12 2013-01-30 Тарганта Терапьютикс Корп. Способ ингибирования клостридиум диффициле введением оритаванцина
CA2730274A1 (en) * 2008-07-07 2010-01-14 Activbiotics Pharma, Llc Use of rifalazil to treat colonic disorders
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
SMT202400116T1 (it) * 2008-10-02 2024-05-14 Salix Pharmaceuticals Ltd Trattamento dell’encefalopatia epatica utilizzando rifaximina
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
MX348670B (es) 2009-02-11 2017-06-23 Cedars Sinai Medical Center Anticuerpo contra toxina de distensión citoletal de campylobacter jejuni.
US20110294726A1 (en) * 2009-02-11 2011-12-01 Cedars-Sinai Medical Center Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome
AU2010312309B2 (en) 2009-10-26 2016-10-06 Thomas Julius Borody Novel enteric combination therapy
US20120258936A1 (en) * 2011-04-06 2012-10-11 The Board Of Regents Of The University Of Texas System Inositol hexakisphosphate analogs and uses thereof
KR102203568B1 (ko) 2012-09-17 2021-01-15 세다르스-신나이 메디칼 센터 장 및 방광의 운동 장애 및 섬유근육통의 진단 및 치료
US10172829B2 (en) 2014-06-24 2019-01-08 The Board Of Trustees Of The Leland Stanford Junior University Use of small molecules for the treatment of clostridium difficile toxicity
US20170189444A1 (en) * 2016-01-06 2017-07-06 California Institute Of Technology Polymeric compositions and related systems and methods for regulating biological hydrogels
AU2018212924A1 (en) 2017-01-30 2019-07-04 Cedars-Sinai Medical Center Diagnosis of scleroderma

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1304363C (en) * 1988-11-01 1992-06-30 Takehiko Yamane 3'-hydroxybenzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
IL98087A (en) * 1990-05-04 1996-11-14 Perio Prod Ltd Preparation for dispensing drugs in the colon
US5266315A (en) * 1990-05-07 1993-11-30 Kabushiki Kaisha Miyarisan Seibutsu Igaku Kenkyusho Composite for Clostridium difficile diarrhea and pseudomembranous colitis
US5582837A (en) * 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
JP3492688B2 (ja) * 1992-10-09 2004-02-03 鐘淵化学工業株式会社 微細な造粒体の製造方法
KR100388569B1 (ko) * 1994-04-22 2003-10-11 야마노우치세이야쿠 가부시키가이샤 결장특이적약물방출용경구약제학적제제
US5849327A (en) * 1994-07-29 1998-12-15 Advanced Polymer Systems, Inc. Delivery of drugs to the lower gastrointestinal tract
NZ291659A (en) * 1994-09-06 2001-04-27 Galagen Inc Use in the manufacture of a medicament of an antibody having specific activity against Clostridium difficile, and pharmaceutical compositions comprising Anti-Clostridium difficile bovine immunoglobulin concentrate; for treating diseases associated with Clostridium difficile
FI98343C (fi) * 1995-03-21 1997-06-10 Orion Yhtymae Oy Peroraalinen formulaatio
US5811388A (en) * 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
ES2248908T7 (es) * 1997-06-06 2014-11-24 Depomed, Inc. Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
KR100219918B1 (ko) * 1997-07-03 1999-09-01 김윤 대장선택적 약물전달용 조성물
US6114310A (en) * 1998-01-23 2000-09-05 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
US5968554A (en) * 1998-07-07 1999-10-19 Cascade Development, Inc. A Subsidiary Of Cardinal Health, Inc. Sustained release pharmaceutical preparation
US6316433B1 (en) * 1998-12-18 2001-11-13 Kaneka Corporation Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
US6270755B1 (en) * 1999-05-13 2001-08-07 Geltex Pharmaceuticals, Inc. Anionic polymers as toxin binders
US6696412B1 (en) * 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
US6488962B1 (en) * 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
AU2003239919A1 (en) * 2002-06-03 2003-12-19 Activbiotics, Inc. Intravenous rifalazil formulation and methods of use thereof

Also Published As

Publication number Publication date
EP1545453A1 (de) 2005-06-29
ES2339003T3 (es) 2010-05-14
AU2003268330A1 (en) 2004-03-19
WO2004019907A1 (en) 2004-03-11
DE60330161D1 (de) 2009-12-31
TW200500071A (en) 2005-01-01
JP2006501310A (ja) 2006-01-12
CA2495144A1 (en) 2004-03-11
EP1545453A4 (de) 2005-10-12
EP1545453B1 (de) 2009-11-18
US20040106590A1 (en) 2004-06-03
AU2009225281A1 (en) 2009-10-29

Similar Documents

Publication Publication Date Title
DE60330161D1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
ATE554756T1 (de) Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EP1626730A4 (de) Verfahren, gerät und zusammensetzung zur behandlung von akne
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
ATE453653T1 (de) Platinkomplexe zur behandlung von tumoren
ATE353880T1 (de) Neue verwendung von pyrimidin- oder triazin-2- carbonsäurenitrilen zur behandlung von krankheiten, die mit cysteinproteaseaktivität assoziiert sind, und neue pyridimidin-2- carbonsäurenitrilderivate
ATE428413T1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
DE602004028574D1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
ATE359816T1 (de) Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren
ATE423110T1 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
ATE343398T1 (de) Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge
DE602005021766D1 (de) Verfahren zur behandlung von atherosklerose
ATE406171T1 (de) Aplidine zur behandlung von multiplem myelom
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
AU2002231777A1 (en) Use of mglur5 antagonists for the treatment of pruritic conditions
DE60310920D1 (de) Zusammensetzung, ausrüstung und methode zur reinigung und/oder behandlung von oberflächen
DE602005010258D1 (de) Behandlung von ballastwasser
ATE460168T1 (de) Nicht-radioaktives strontiummittel zur behandlung von krebs
ATE291425T1 (de) R-eliprodil zur behandlung von glaucoma
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
ATE412423T1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties